Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Risk of anaphylaxis associated with cold urticaria
Authors:ID Bizjak, Mojca, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author)
ID Rutkowski, Krzysztof (Author)
ID Assero, Ricardo (Author)
Files:URL URL - Source URL, visit https://link.springer.com/article/10.1007/s40521-024-00366-9
 
.pdf PDF - Presentation file, download (803,06 KB)
MD5: 6E2A0B4C9AE7F899508631F5BDFD49BD
 
Language:English
Typology:1.02 - Review Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Purpose of review Cold-induced anaphylaxis (ColdA) is a poorly understood form of anaphylaxis that occurs in patients with cold urticaria (ColdU). This comprehensive review aims to deepen the understanding of ColdA. It emphasizes the identification of high-risk ColdU patients susceptible to ColdA and provides recommendations for their effective management. Recent findings Recent studies, including the large international COLD-CE study, have identified clinical features of ColdU patients associated with increased ColdA risk. These individuals can now be recognized through routine clinical assessments. Key diagnostic indicators for assessing ColdU and the risk of ColdA include oropharyngeal/laryngeal symptoms and positive standard local cold provocation tests. ColdA has been defined as acute cold-induced involvement of the skin and/or visible mucosal tissue accompanied by cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms, but a universally accepted definition is lacking. Additionally, ColdA has recently been recognized as an indication for prescribing adrenaline (epinephrine) autoinjectors, marking a significant advancement in disease management. Summary ColdA is a major and potentially life-threatening concern for a subset of ColdU patients. Early recognition of high-risk patients, coupled with education and preparedness of both patients and healthcare providers, is crucial for effectively managing this challenging condition. Further research is needed to expand understanding of the underlying pathophysiological mechanisms of ColdA, identify potential cofactors influencing ColdA, and improve disease-management strategies.
Keywords:adrenaline (epinephrine), autoinjector, cold-induced anaphylaxis, cold urticaria, management, risk factors
Publication status:Published
Publication version:Version of Record
Article acceptance date:06.06.2024
Publication date:20.06.2024
Publisher:Springer
Year of publishing:2024
Number of pages:str. 167–175
Numbering:Vol. 11, [iss. 3]
Source:Current treatment options in allergy
PID:20.500.12556/DiRROS-22523 New window
UDC:616
ISSN on article:2196-3053
DOI:10.1007/s40521-024-00366-9 New window
COBISS.SI-ID:200488451 New window
Copyright:© The Author(s) 2024 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publication date in DiRROS:28.05.2025
Views:445
Downloads:264
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Current treatment options in allergy
Publisher:Springer
ISSN:2196-3053
COBISS.SI-ID:530011929 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0360
Name:Celostna obravnava alergijskih bolezni in astme v Sloveniji: od epidemiologije do genetike

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:20.06.2024
Applies to:Version of Record valid from 2024-06-20

Secondary language

Language:Slovenian
Keywords:alergije, epinefrin, samoinjektor, anafilaksija na hlad, urtikarija zaradi mraza, obvladovanje, dejavniki tveganja


Back